Natco Pharma Limited has informed the bourses that it has received emergency use approval for Baricitinib tablets in strengths of 1 mg, 2 mg, and 4 mg from Central Drugs Standard Control Organisation (CDSCO), India. Baricitinib, combined with Remdesivir, is used for the treatment of COVID-19 positive patients.